Press Releases

Mylan to Acquire the Global Marketing Rights to a Once-monthly Glatiramer Acetate Product through an Investment and Partnership with Israeli Company Mapi Pharma

Mylan to Acquire the Global Marketing Rights to a Once-monthly Glatiramer Acetate Product through an Investment and Partnership with Israeli Company Mapi Pharma

Once approved, this product could represent a significant milestone for patients with relapsing-remitting multiple sclerosis   Mapi Pharma has completed an open-label Phase II clinical trial and is preparing to commence a pivotal Phase III clinical trial to support marketing applications   HERTFORDSHIRE, England and PITTSBURGH and…

Continue reading →

Mapi Pharma to Host Key Opinion Leader Meeting on Long Acting Glatiramer Acetate (GA Depot) for Multiple Sclerosis

Mapi Pharma to Host Key Opinion Leader Meeting on Long Acting Glatiramer Acetate (GA Depot) for Multiple Sclerosis

NESS ZIONA, Israel – February 6, 2018 – Mapi Pharma Ltd., a fully integrated, clinical late stage biopharmaceutical company, announced today that it will host a Key Opinion Leader (KOL) luncheon on its GA Depot, a novel long-acting depot formulation of glatiramer acetate for multiple…

Continue reading →

First Patient Treated in Mapi Pharma’s Phase II Clinical Trial  of GA Depot for Primary Progressive Multiple Sclerosis (PPMS)

First Patient Treated in Mapi Pharma’s Phase II Clinical Trial of GA Depot for Primary Progressive Multiple Sclerosis (PPMS)

Study is being conducted on strength of prior Phase II clinical trial that showed strong efficacy in RRMS patients who switched from Copaxone® to once-monthly GA Depot Ness Ziona, Israel, January 30th, 2018 — Mapi Pharma Ltd. announced today that the first patient has been…

Continue reading →

Mapi Pharma Announces Presentation of Phase II Results of Glatiramer Acetate Depot at ECTRIMS-ACTRIMS 2017 Congress in Paris

Mapi Pharma Announces Presentation of Phase II Results of Glatiramer Acetate Depot at ECTRIMS-ACTRIMS 2017 Congress in Paris

  Data Suggest that GA Depot Has Potential to Ease the Treatment Burden and Improve Patient Compliance in MS Patients on GA Depot Achieved a No Evidence of Disease Activity (NEDA) Score of 84.6% Phase III Trial Planned for 2018   NESS ZIONA, Israel –…

Continue reading →

Mapi Pharma Ltd. Announces Closing of $10 Million Investment

Mapi Pharma Ltd. Announces Closing of $10 Million Investment

NESS ZIONA, Israel, August 17, 2017. Mapi Pharma Ltd., a privately held, fully integrated, clinical stage biopharmaceutical company has completed an investment round of $10 million by aMoon Fund. aMoon Fund is an Israeli investment firm focused on innovative Israeli healthcare and life science ventures,…

Continue reading →

Mapi Pharma Closes $10 Million Investment Led by Shavit Capital

Mapi Pharma Closes $10 Million Investment Led by Shavit Capital

Ness Ziona, Israel, May 27, 2015 — Mapi Pharma Ltd. announced today that Shavit Capital has led an investment round of $10 million in the company in a Series A financing round that included participation by the company’s chairman and CEO Mr. Ehud Marom.   The…

Continue reading →

First Patient Treated in Mapi Pharma’s Phase IIa Clinical Trial  of GA Depot for Relapsing Remitting Multiple Sclerosis (RRMS)

First Patient Treated in Mapi Pharma’s Phase IIa Clinical Trial of GA Depot for Relapsing Remitting Multiple Sclerosis (RRMS)

Ness Ziona, Israel, December 17, 2014 — Mapi Pharma Ltd. announced today that the first patient was treated in the company’s Phase IIa study of GA Depot, in development as a treatment for relapsing remitting multiple sclerosis (RRMS).  Glatiramer Acetate is the active ingredient in…

Continue reading →

Mapi Pharma Receives Additional Claims for Its U.S. Patent for Glatiramer Acetate Depot for the Treatment of Multiple Sclerosis

Mapi Pharma Receives Additional Claims for Its U.S. Patent for Glatiramer Acetate Depot for the Treatment of Multiple Sclerosis

GA Depot Patent Release – May 27 2014 Ness Ziona, Israel, May 27, 2014 —- Mapi Pharma Ltd. (“Mapi” or the “Company”), a developer of high-barrier to entry and high value-added generic drugs, announced today that its US patent for the company’s Glatiramer Acetate Depot…

Continue reading →

Mapi Pharma Granted United States Patent for the Preparation of Fingolimod for Multiple Sclerosis

Mapi Pharma Granted United States Patent for the Preparation of Fingolimod for Multiple Sclerosis

Tuesday, February 18, 2014 Mapi Pharma Granted United States Patent Covering the Process for the Preparation of Fingolimod for Multiple Sclerosis The patent covers intermediate compounds and processes for the preparation of Fingolimo Mapi Pharma Ltd. (“Mapi” or the “Company”), a developer of high-barrier to…

Continue reading →

Mapi Pharma Granted United States Patent for Pain Relief Medication “Tapentadol”

Mapi Pharma Granted United States Patent for Pain Relief Medication “Tapentadol”

Tuesday, June 18, 2013 Mapi Pharma Granted United States Patent for Pain Relief Medication “Tapentadol” The patent covers the process and preparation of Tapentadol for the treatment of moderate to severe-acute pain Mapi Pharma Ltd. (Mapi), developer of complex bulk Active Pharmaceutical Ingredients (APIs), generic…

Continue reading →

Mapi Pharma Granted United States Patent covering Glatiramer Depot for Multiple Sclerosis

Mapi Pharma Granted United States Patent covering Glatiramer Depot for Multiple Sclerosis

Morbi posuere, augue adipiscing cursus ullamcorper, turpis urna volutpat urna, a pulvinar massa sem sit amet diam. Etiam at ante erat, id aliquam nisi. Integer vitae nibh tellus. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Morbi rhoncus lorem ac risus iaculis adipiscing. Sed sollicitudin euismod velit. Suspendisse pretium tempus sollicitudin. Proin augue felis, posuere id elementum et, accumsan at sem. Vivamus non facilisis quam. Nunc pellentesque pulvinar vestibulum. Aliquam convallis erat a enim dictum et vestibulum nibh rutrum. In mi nisi, hendrerit in pellentesque pellentesque, blandit a ipsum. Nam aliquet commodo nulla nec lobortis. Curabitur aliquet, urna a tempus iaculis, lorem augue tristique augue, sed aliquet sapien ligula nec lorem.

Continue reading →